<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To extend the use of allogeneic hematopoietic cell transplantation (HCT) to patients without an HLA-matched donor, we investigated HCT from a related donor with 1 fully mismatched HLA-haplotype after conditioning with <z:chebi fb="0" ids="28901">busulfan</z:chebi> in reduced-dose, fludarabine, and antithymocyte globulin </plain></SENT>
<SENT sid="1" pm="."><plain>Hematopoietic cells were collected from the donors via leukapheresis after mobilization and infused without further manipulation </plain></SENT>
<SENT sid="2" pm="."><plain>Cyclosporin and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> were administered for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prophylaxis </plain></SENT>
<SENT sid="3" pm="."><plain>Posttransplant engraftment, GVHD, and transplantation-related mortality (TRM) were recorded </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty-one patients (age range: 16-69 years) with high-risk <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n = 25) or <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> (n = 6) were enrolled </plain></SENT>
<SENT sid="5" pm="."><plain>The donors were either mothers (n = 14), offspring (n = 9), or siblings (n = 8) of these patients </plain></SENT>
<SENT sid="6" pm="."><plain>Excluding 3 patients who died or relapsed with <z:hpo ids='HP_0001909'>leukemia</z:hpo> within 3 weeks after HCT, <z:hpo ids='HP_0000001'>all</z:hpo> the remaining 28 patients engrafted with neutrophils (&gt;500/microL) at a median of 16.5 days </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-two of 24 evaluated patients achieved complete donor chimerism (&gt; or =95%) 2 weeks after HCT and none experienced graft failure subsequently </plain></SENT>
<SENT sid="8" pm="."><plain>The cumulative incidences of grade 2-4 <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (aGVHD) and moderate-severe <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (cGVHD) were 19% (95% confidence interval [CI], 9%-40%) and 20% (95% CI, 10%-41%), respectively </plain></SENT>
<SENT sid="9" pm="."><plain>After a median follow-up of 18.2 months (range: 6.3-52.1), 18 patients remained alive (53%) </plain></SENT>
<SENT sid="10" pm="."><plain>Four patients died without recurrence/progression of underlying diseases giving a TRM of 13% (95% CI, 5%-33%) </plain></SENT>
<SENT sid="11" pm="."><plain>HCT from an HLA-mismatched family member is feasible without ex vivo T cell <z:mpath ids='MPATH_63'>depletion</z:mpath> when reduced-intensity conditioning containing anti-hymocyte globulin is performed </plain></SENT>
</text></document>